Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019

Global Markets Direct
142 Pages - GMD17868
$2,000.00

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.

Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 4, 19, 6 and 2 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

'

Table of Contents
Table of Contents
Introduction
Post-Traumatic Stress Disorder (PTSD) - Overview
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment
Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development
Post-Traumatic Stress Disorder (PTSD) - Drug Profiles
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products
Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones
Appendix


List of Tables
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Actinogen Medical Ltd, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Anagin Inc, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aptinyx Inc, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Armgo Pharma Inc, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Artelo Biosciences Inc, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Co, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Johnson & Johnson, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Lixte Biotechnology Holdings Inc, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sanofi, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by SpringWorks Therapeutics LLC, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2019
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H1 2019 (Contd..1), H1 2019
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H1 2019

List of Figures
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838